- Previous Close
2.7000 - Open
2.5800 - Bid --
- Ask --
- Day's Range
2.5800 - 2.6900 - 52 Week Range
2.5100 - 5.9000 - Volume
4,257 - Avg. Volume
4,378 - Market Cap (intraday)
11.22M - Beta (5Y Monthly) 1.33
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6000 - Earnings Date Apr 28, 2025 - May 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.00
STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. The company products include XTRAC and Pharos excimer lasers, and VTRAC lamp systems for the treatment systems that are used for the treatment of psoriasis, vitiligo, and other skin conditions. It also offers TheraClear Acne Therapy System for the treatment of mild to moderate inflammatory, comedonal, and pustular acne. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
www.strataskinsciences.comRecent News: SSKN
View More
Performance Overview: SSKN
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SSKN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SSKN
View MoreValuation Measures
Market Cap
11.22M
Enterprise Value
20.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.30
Price/Book (mrq)
1.20
Enterprise Value/Revenue
0.63
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-28.72%
Return on Assets (ttm)
-8.85%
Return on Equity (ttm)
-73.49%
Revenue (ttm)
32.67M
Net Income Avi to Common (ttm)
-9.38M
Diluted EPS (ttm)
-2.6000
Balance Sheet and Cash Flow
Total Cash (mrq)
7.06M
Total Debt/Equity (mrq)
176.36%
Levered Free Cash Flow (ttm)
3.93M